Commonwealth Equity Services
PMCB icon

Commonwealth Equity Services’s PharmaCyte Biotech PMCB Stock Holding History

Commonwealth Equity Services’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.86K Buy
+10,313
New +$7.89K ﹤0.01% 4289

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Commonwealth Equity Services's PMCB Position: Q1 2026 in Review

Commonwealth Equity Services opened a new position in PharmaCyte Biotech (PMCB) in Q1 2026: 10,313 shares worth $6.86K. The stake represents ﹤0.01% of the portfolio and ranks #4289 among its holdings.

32 funds tracked by Wall St. Rank hold PMCB as of Q1 2026.

  • Commonwealth Equity Services held 10,313 shares of PharmaCyte Biotech worth $6.86K as of Q1 2026.
  • PharmaCyte Biotech was a new Commonwealth Equity Services position in Q1 2026.
  • PharmaCyte Biotech made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q1 2026, its #4289 holding.
  • 32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2026.

Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.